[Federal Register Volume 64, Number 156 (Friday, August 13, 1999)]
[Notices]
[Page 44232]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-20938]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: A Basal Cell Carcinoma 
Tumor Suppressor Gene

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license worldwide to practice the invention embodied in: 
U.S. Patent Application Serial No. 08/857,636 filed May 16, 1997 
entitled ``A Basal Cell Carcinoma Tumor Suppressor Gene'', PCT 
application US97/08433 filed May 16, 1997 designating all countries, 
except the U.S., entitled, ``A Basal Cell Carcinoma Tumor Suppressor 
Gene'' to Ontogeny, Inc., having a place of business in Cambridge, MA. 
The United States of America is the assignee or the exclusive licensee 
of the patent rights in this invention.

DATES: Only written comments and/or application for a license which are 
received by the NIH Office of Technology Transfer on or before October 
12, 1999.

ADDRESSES: Requests for a copy of the patent applications, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to Richard U. Rodriguez, M.B.A., at the Office of 
Technology Transfer, National Institutes of Health, 6011 Executive 
Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 496-
7056, ext. 287; Facsimile: (301) 402-0220; E-mail: [email protected].

SUPPLEMENTARY INFORMATION: In an effort to develop a method of 
detection and an efficacious treatment for basal cell carcinoma, nevoid 
basal cell carcinoma syndrome, and medulloblastoma, the inventors posit 
that the Basal Cell Carcinoma Tumor Suppressor Gene and the disclosed 
mutations thereof may play a key physiological role.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be limited to the fields of human 
diagnostics and therapeutics for indications consisting of nevoid basal 
cell carcinoma syndrome, basal cell carcinoma, and medulloblastoma and 
may be granted unless, within 60 days from the date of this published 
Notice, NIH receives written evidence and argument that establishes 
that the grant of the license would not be consistent with the 
requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: August 6, 1999.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 99-20938 Filed 8-12-99; 8:45 am]
BILLING CODE 4140-01-M